Trump’s new tariff plan targets overseas generic drugs with 100% duties starting in August 2028, escalating to 200% by August 2029, aiming to force manufacturers to reshore production to the U.S. Most generics are made in India, with ingredients from China, raising fears of supply chain risks. While the move could boost American jobs and resilience, experts warn high tariffs may drive up prices, cause shortages, or push companies out of the market. This isn’t the first time Trump has used tariffs to pressure pharma — past moves spurred brand-name drug makers to invest in U.S. facilities, and this could be the opening gambit in negotiations with generic drugmakers.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
